Zika Virus in depth.
A mild illness in most adults, but a devastating threat to unborn children — Zika's capacity to cause microcephaly and other severe birth defects shocked the world in 2015–2016.
Overview
Zika virus disease is a mosquito-borne flaviviral infection known for its devastating effects on fetal neurodevelopment. Caused by Zika virus (ZIKV, Flaviviridae), it spreads primarily through the bite of infected Aedes aegypti mosquitoes, and also through sexual transmission and from mother to fetus. Key symptoms: mild fever, rash, joint pain, and conjunctivitis. Most adults have mild illness; the critical concern is congenital Zika syndrome, including microcephaly, in babies born to infected mothers.
Zika infection in adults is typically mild — 80% of infected individuals remain asymptomatic, and symptomatic cases cause a self-limiting illness with fever, rash, joint pain, and conjunctivitis. However, Zika's greatest threat is to unborn children: maternal Zika infection during pregnancy — particularly in the first trimester — causes Congenital Zika Syndrome (CZS), characterized by microcephaly (abnormally small head and brain), intracranial calcifications, eye defects, joint abnormalities, and other neurological damage. The 2015–2016 Americas outbreak produced over 3,500 confirmed microcephaly cases in Brazil alone.
Zika also causes Guillain-Barré Syndrome (GBS) — an autoimmune paralysis — at a rate of ~2 per 10,000 infections. The 2016 WHO PHEIC declaration (lifted November 2016) led to accelerated research into Zika vaccines and therapeutics, though no licensed vaccine exists as of 2025. Zika remains endemic in tropical regions and continues to pose a risk, particularly for pregnant women travelling to or residing in endemic areas.
History & Origin
Zika virus was first isolated in 1947 in Uganda. Human serological evidence from Uganda and Tanzania followed in 1952. Sporadic human cases were reported in Africa and Asia for decades. The first documented outbreak outside Africa was in Yap Island (Micronesia) in 2007 (49 cases). In 2013–2014, French Polynesia experienced the first large Zika epidemic (~28,000 cases) — also the first outbreak to document Guillain-Barré Syndrome association.
The explosive 2015–2016 Brazil outbreak — linked to the simultaneous unprecedented surge of microcephaly cases — led to the WHO declaring a PHEIC on 1 February 2016. The outbreak spread through the Caribbean, Latin America, and the Pacific. The causal link between maternal Zika infection and congenital microcephaly was established by mid-2016, representing one of the most significant causal discoveries in modern epidemiology. Over 87 countries reported locally acquired Zika transmission.
Transmission
- Mosquito (primary route): Aedes aegypti (tropical urban) and Aedes albopictus (wider range including temperate regions). Same vectors as dengue and chikungunya; similar prevention measures apply.
- Sexual transmission: Zika can spread from an infected person to their sexual partners through vaginal, anal, or oral sex. Virus persists in semen for up to 3 months; in vaginal secretions for ~2 weeks; in blood for ~10 days. Both symptomatic and asymptomatic individuals can transmit sexually.
- Mother to child: Vertical transmission during pregnancy causes Congenital Zika Syndrome. Transmission can occur at any gestational age; risk is highest in the first trimester when neural tube formation occurs.
- Blood transfusion and organ donation: Documented transmission; blood banks in outbreak areas screen for ZIKV.
- Laboratory exposure: Biosafety precautions required when handling Zika specimens.
Symptom Timeline
Incubation: 3–14 days after mosquito bite. 80% of infections are asymptomatic.
- Low-grade fever (rarely >38.5°C)
- Maculopapular pruritic rash — often the most prominent symptom, spreading from face to body
- Bilateral conjunctivitis (non-purulent, red eyes)
- Arthralgia — particularly hands and feet; joint swelling
- Myalgia, headache, fatigue
- Symptoms are typically mild and self-limiting, resolving within 2–7 days
- GBS onset typically 1–6 weeks after Zika infection (post-infectious immune complication)
- Progressive ascending weakness: starts in legs, can spread to arms and breathing muscles
- Tingling and numbness; loss of deep tendon reflexes
- In severe cases: respiratory failure requiring mechanical ventilation
- Most patients recover, but recovery can take months; ~5% have permanent disability
- Microcephaly: head circumference >3 SD below mean; associated with severe brain damage, intellectual disability, seizures
- Intracranial calcifications (visible on CT/MRI)
- Cortical malformations: pachygyria (simplified gyral pattern), lissencephaly, polymicrogyria
- Ophthalmological abnormalities: chorioretinal scarring, optic nerve hypoplasia, cataracts
- Joint abnormalities: clubfoot, arthrogryposis
- Muscle hypertonia; hearing loss; developmental delays
- Risk in first trimester highest (~1–13% risk of CZS if infected in T1); risk decreases but persists in later pregnancy
Diagnosis
- RT-PCR (viraemia phase): Detection of ZIKV RNA in blood (up to 7 days), urine (up to 14 days), or semen (up to 3 months). Urine is preferred over blood for PCR diagnosis when >5 days since symptom onset.
- IgM serology (ELISA): IgM detectable from day 4 of illness; cross-reacts with dengue and other flaviviruses — requires confirmatory plaque reduction neutralisation test (PRNT).
- PRNT: Gold standard for serological confirmation; distinguishes Zika from dengue and other flaviviruses.
- Prenatal diagnosis: Amniocentesis with RT-PCR on amniotic fluid; foetal ultrasound for microcephaly and brain abnormalities (may not be apparent until 24–28 weeks). MRI for detailed brain evaluation.
- Differential diagnosis: Dengue, chikungunya, rubella, measles, parvovirus B19, rickettsia infections share overlapping presentations.
Treatment
No specific antiviral treatment or approved vaccine for Zika exists. Management is supportive.
- Paracetamol for fever and pain
- Rest and adequate hydration
- Avoid NSAIDs and aspirin until dengue is excluded (bleeding risk)
- GBS management: IVIG or plasmapheresis; mechanical ventilation if respiratory muscles affected; physiotherapy for recovery
- CZS: lifelong multidisciplinary support — neurology, physiotherapy, occupational therapy, education support; no specific treatment reverses brain damage
Prevention & Pregnancy Precautions
- Pregnant women should avoid travel to Zika-endemic areas if at all possible. If travel is unavoidable, use maximum mosquito bite prevention measures throughout the trip and for 3 months after return.
- Sexual transmission prevention during pregnancy: If male partner has been to a Zika area, use condoms or abstain from sex for the entire pregnancy (or 3 months after their exposure, whichever is longer). If female partner was exposed: use condoms for 2 months.
- Mosquito protection: EPA-approved repellents (DEET ≥20%, picaridin); permethrin-treated clothing; long sleeves/trousers; windows/door screens; daytime bite protection.
- No approved vaccine: Multiple vaccine candidates in clinical trials (including mRNA vaccines). WHO and NIH list Zika vaccine development as a research priority. Funding has declined since the 2016 emergency.
Global Impact
The 2015–2016 Zika pandemic caused an estimated 1.5 million+ cases in Brazil and spread to 87 countries. Brazil reported ~3,500 confirmed cases of microcephaly associated with Zika — a 10-fold increase over baseline. The social impact was enormous: emergency declarations, travel advisories affecting the 2016 Rio Olympics, financial devastation for families caring for severely disabled children, and billions in estimated economic costs.
Zika remains endemic in parts of Latin America, the Caribbean, Asia, and Africa. Without mass immunity or a vaccine, populations remain susceptible to future outbreaks. The CZS children from the 2015–2016 epidemic now represent a large cohort of children requiring lifelong care — highlighting Zika's long-term societal consequences beyond the outbreak itself. There are ongoing concerns that climate change expanding Aedes mosquito ranges could bring Zika to new regions.
History: From African Forests to Global Crisis
Zika virus was first isolated in 1947 from a sentinel rhesus monkey in the Zika Forest of Uganda during yellow fever research. The first documented human cases were recorded in Nigeria (1954) and Uganda (1962). For decades, Zika caused mild, self-limiting illness and was considered a minor pathogen — only around 14 human cases were documented between 1952 and 2007.
The epidemiological picture changed dramatically in 2007, when an outbreak struck Yap Island (Micronesia) — an unprecedented geographic jump. The 2013–2014 French Polynesia outbreak (around 30,000 symptomatic cases) was the first to link Zika with Guillain-Barré syndrome. The 2015–2016 Brazil epidemic was the defining global event: Brazil reported an explosive 4000% surge in microcephaly cases, eventually confirming Zika as the cause of congenital Zika syndrome (CZS). WHO declared a Public Health Emergency of International Concern (PHEIC) in February 2016 — the most significant PHEIC since Ebola in West Africa.
- 1947: Isolated from monkey, Zika Forest, Uganda
- 1952: First human cases documented in Uganda and Tanzania
- 2007: Yap Island (Micronesia) — first Pacific outbreak; 73% population seroprevalence
- 2013–2014: French Polynesia — first link to Guillain-Barré syndrome; estimated 32,000 cases
- 2015–2016: Brazil and Americas — epidemic affecting 48 countries/territories; congenital microcephaly epidemic; WHO PHEIC declared Feb 2016
- 2016: WHO PHEIC ended November 2016; Zika remains endemic in parts of Americas, Southeast Asia, Pacific
Congenital Zika Syndrome: Mechanism & Spectrum
Zika virus causes congenital brain abnormalities through direct infection of neural progenitor cells — the cells that give rise to the developing brain. ZIKV infects these cells via AXL and other entry receptors, replicates, and causes apoptosis (cell death) or impairs proliferation — resulting in reduced cortical neuron production and microcephaly. The timing of maternal infection is critical: first-trimester infection carries the highest risk of severe fetal brain malformations.
Congenital Zika Syndrome (CZS) Features
- Microcephaly: Head circumference >2 SD below mean for gestational age and sex; cortical malformations including lissencephaly, pachygyria, simplified gyral pattern
- Intracranial calcifications: Subcortical, basal ganglia — visible on head ultrasound and CT
- Eye abnormalities: Macular atrophy, chorioretinal scarring, optic nerve abnormalities
- Contractures/hypertonia: Joint contractures, hypertonia due to brain damage
- Ventriculomegaly: Enlarged brain ventricles due to reduced brain volume
- Late-emerging neurodevelopmental features: Children with CZS may have normal-sized heads at birth but develop microcephaly postnatally; epilepsy, intellectual disability, hearing loss emerge over time
Estimated 5–15% of Zika-infected pregnancies result in birth defects or fetal loss, though this varies significantly by trimester and individual factors.
Sexual Transmission: A Unique Feature
Zika is exceptional among mosquito-borne diseases in having confirmed sexual transmission — making it the first arbovirus with this route. ZIKV RNA has been detected in semen for up to 6 months after acute infection (sometimes longer) and in vaginal secretions. Transmission from infected males to female partners (and in rare cases, female to male and male to male) has been documented. This has critical implications for pregnancy planning:
- Men with confirmed Zika infection or symptoms of Zika should use condoms or abstain from sex for at least 3 months after symptom onset/travel to endemic area
- Men with recent travel to Zika-endemic areas (no symptoms): condoms for at least 2 months
- Women who are pregnant or trying to conceive should avoid travel to active Zika transmission areas; if travel is unavoidable, use mosquito protection rigorously
- Partners of pregnant women who have been exposed: use condoms throughout pregnancy
Guillain-Barré Syndrome (GBS) & Neurological Complications
Guillain-Barré syndrome is an autoimmune peripheral neuropathy where the immune system attacks the myelin sheath around nerves. During the French Polynesia outbreak, the GBS incidence was 0.24 per 1,000 Zika infections — approximately 20× higher than the background rate. In Brazil 2015–2016, GBS cases increased 2–10-fold in regions of high Zika activity. Most Zika-associated GBS cases recover with supportive care (IVIg or plasmapheresis); ~5–10% have residual weakness.
Other neurological complications linked to Zika include: encephalitis and myelitis (spinal cord inflammation); acute flaccid paralysis; and in congenitally affected children — epilepsy, cortical visual impairment, and cerebral palsy.
Diagnosis: Challenges with Cross-Reactivity
Zika diagnosis is complicated by cross-reactivity with other flaviviruses, particularly dengue. IgM and IgG antibodies produced against ZIKV can react in dengue serological tests (and vice versa), leading to false-positive results in dengue-endemic areas. This requires confirmatory testing by plaque-reduction neutralization tests (PRNT) at reference laboratories.
- RT-PCR: Gold standard in the first 7 days of illness (viraemia window). Urine RT-PCR may be positive for 1–2 weeks after symptom onset (longer than blood). In pregnancy, amniotic fluid PCR can confirm fetal infection.
- IgM serology (ELISA): From day 5 onwards; cross-reactivity with dengue is a major limitation. Positive IgM in flavivirus-endemic regions requires PRNT confirmation.
- PRNT: Gold standard for serology confirmation; measures ability of patient antibodies to neutralize ZIKV in cell culture; performed only in reference labs.
- Fetal imaging: Cranial ultrasound (can detect microcephaly, calcifications from 28 weeks); MRI for detailed brain anatomy assessment.
Pregnancy Management & Current Guidance
- Pregnant women should avoid non-essential travel to areas with active Zika transmission
- If Zika exposure occurred, serial fetal ultrasound monitoring every 3–4 weeks is recommended; MRI if structural anomalies suspected
- No specific antiviral treatment for maternal Zika infection; symptomatic treatment only (paracetamol for fever — not NSAIDs)
- Newborns of Zika-exposed mothers should have head circumference measured, hearing tested, ophthalmology evaluation, and developmental follow-up
- Breastfeeding: ZIKV RNA detected in breast milk, but WHO considers benefits of breastfeeding to outweigh risk; breastfeeding not contraindicated in Zika-exposed mothers
Vaccine Pipeline & Research Status
No Zika vaccine has been licensed as of 2025, despite the 2015–2016 crisis triggering intense development efforts. The decline in cases after 2017 has made Phase 3 efficacy trials difficult (lack of endpoints), slowing progress.
- ZPIV (mRNA-1325, Moderna): mRNA vaccine in Phase 2 trials; strong immunogenicity; Phase 3 awaiting sufficient epidemic conditions
- VRC 5283 (NIH/NIAID): DNA vaccine; Phase 2 trial showed good immunogenicity and safety; Phase 3 design pending
- MV-ZIKA (Themis): Measles vector-based vaccine; preclinical data promising
- Novel antivirals: Sofosbuvir (hepatitis C drug) shows anti-ZIKV activity in vitro; RNA polymerase inhibitors under investigation
- Sterile insect technique & Wolbachia: Aedes aegypti control using sterile males and Wolbachia mosquitoes being trialed in Zika-endemic regions
Country-Specific Information
Frequently Asked Questions
Sources & Citations
Blood Transfusion & Organ Transplant Risk
Zika virus can be transmitted through blood transfusion — viremic but asymptomatic donors can contaminate the blood supply. During the 2016 Americas outbreak, multiple countries implemented blood donor screening (questionnaire-based deferral and nucleic acid testing). The FDA required universal blood donor screening for Zika in Puerto Rico (2016) and later expanded to all US states. Organ and tissue transplant risk is theoretical but has not been well-documented. Blood transfusion screening recommendations vary by country based on local transmission risk.
Zika in 2024–2025: Endemic Status
After the dramatic 2015–2016 epidemic, global Zika case counts fell sharply as population immunity built up across the Americas and Pacific. Zika is now considered endemic (stable, ongoing low-level transmission) in parts of Latin America, the Caribbean, Southeast Asia, and the Pacific. Occasional local outbreaks continue — India (2021, 2023), Brazil, and scattered cases in returning travellers.
A key concern is Zika's potential resurgence when a new non-immune birth cohort grows up without prior exposure. The 2015 epidemic created population immunity across the Americas; as this wanes over 5–10 years (especially in children born after the epidemic) and if Aedes aegypti remains prevalent, conditions for a new epidemic wave could emerge — particularly if a vaccine has not been deployed by then.
Travel medicine clinics continue to advise travellers to Zika-endemic regions on mosquito protection and sexual transmission precautions. Pregnant women or those planning pregnancy are counselled to defer non-essential travel to active Zika areas.
Living with Congenital Zika Syndrome
Children with congenital Zika syndrome (CZS) require multidisciplinary long-term care. Brazil established specialized CZS care networks for the thousands of affected children from the 2015–2016 epidemic, providing important lessons in caring for CZS:
- Neurology: Epilepsy management (often medically refractory — multiple anticonvulsants may be needed); EEG monitoring; botulinum toxin for spasticity
- Developmental therapy: Early intervention physiotherapy, occupational therapy, speech and feeding therapy — maximizes neurodevelopmental potential
- Ophthalmology: Regular eye exams; treatment of refractive errors, strabismus, and retinal pathology
- Hearing: Regular audiology assessment; hearing aids or cochlear implants if indicated
- Nutrition: Feeding difficulties, dysphagia, and aspiration are common in CZS; nasogastric or gastrostomy feeding in severe cases
- Family support: Primary caregivers (often mothers) experience high rates of depression, burnout, and social isolation; psychosocial support services critical
- Social/educational: Many CZS children have severe intellectual disability requiring specialized education and social services for life
Related Diseases
Key Terms: Zika Virus
- ZIKV: Zika virus — an Aedes mosquito-transmitted Flavivirus; related to dengue, West Nile, and yellow fever viruses
- CZS: Congenital Zika Syndrome — the spectrum of birth defects caused by maternal Zika infection including microcephaly, brain malformations, eye abnormalities, and contractures
- Microcephaly: A birth defect where a baby's head is significantly smaller than expected, associated with underdevelopment of the brain; the hallmark of severe CZS
- GBS: Guillain-Barré Syndrome — an autoimmune neurological condition where the immune system attacks peripheral nerves; a rare complication of Zika infection in adults
- PRNT: Plaque-Reduction Neutralization Test — the gold standard serological test for flaviviruses; measures ability of antibodies to neutralize viral infection in cell culture; needed to confirm Zika serology due to cross-reactivity with dengue
- Sexual transmission: Zika's unique characteristic among arboviruses — ZIKV can be transmitted through vaginal and anal intercourse, and via oral sex; ZIKV RNA persists in semen for up to 6 months
- Neural progenitor cells: Stem cells that give rise to neurons in the developing brain; primary target of Zika virus infection causing microcephaly through cell death and impaired proliferation
- AXL receptor: A tyrosine kinase receptor expressed on neural progenitor cells and other cell types; one of several entry receptors used by Zika virus to infect cells
- PHEIC: Public Health Emergency of International Concern — the highest-level WHO alert; Zika was declared a PHEIC in February 2016 due to the microcephaly epidemic in Brazil
- Teratogen: An agent that causes birth defects; Zika virus is now confirmed as a teratogen — one of the few viruses directly proven to cause fetal malformations
More Zika Questions
Epidemiology at a Glance: Zika Virus
| Region | Burden | Notes |
|---|---|---|
| Brazil (2015–2016) | >1.5M suspected cases; ~3,500+ confirmed CZS microcephaly cases | Epicenter of 2015 epidemic; first recognition of Zika-microcephaly link; Olympic Games contingency plans activated |
| Americas total (2015–2017) | >700,000 confirmed cases across 48 countries/territories | Includes Colombia (~100K cases), Venezuela (~64K), Honduras, Dominican Republic, Puerto Rico, etc. |
| Pacific Islands (2007, 2013–2014) | Yap Island 2007 (~5K); French Polynesia 2013 (~30K) | First pandemic-scale spread outside Africa/Asia; French Polynesia first linked Zika to GBS |
| Southeast Asia | Endemic; Singapore 2016 (460 cases); India, Thailand, Vietnam ongoing sporadic transmission | Asian lineage ZIKV; less severe CZS risk? (controversial — possible host/virus interaction differences) |
| Africa | Endemic in West and Central Africa; historically low documented disease burden | Possible prior immunity from historic exposure; less surveillance infrastructure |
| Current global status (2024) | Endemic, low-level transmission in parts of Americas, Asia, Pacific | No active outbreak of 2015–2016 scale; population immunity plus epidemic waning; risk persists for seronegative individuals |
Zika Prevention Checklist — Special Focus on Pregnancy
- For pregnant women: Avoid non-essential travel to countries with active Zika transmission. Consult a travel medicine specialist if travel to endemic areas is unavoidable.
- Mosquito protection in endemic areas: Use EPA-registered repellents (DEET 30%+, picaridin) even indoors; wear long-sleeved clothing; use air conditioning or screened windows; sleep under bed nets.
- Sexual transmission prevention — male partner exposed/infected: Use condoms consistently for at least 3 months after symptom onset or potential exposure. For partners of pregnant women: use condoms for the entire pregnancy.
- Female partner exposed/infected (not pregnant): Wait at least 2 months before attempting to conceive.
- If pregnant and diagnosed with Zika: Serial fetal ultrasound monitoring every 3–4 weeks; discuss amniocentesis to confirm fetal infection with your specialist; pediatric and neonatology consultation antenatally.
- Blood donation: Do not donate blood for 28 days after returning from a Zika-endemic area or confirmed/suspected Zika illness.
- Newborns of Zika-exposed pregnancies: Head circumference, eye exam, hearing test, and developmental follow-up for all newborns born to mothers with confirmed/suspected Zika during pregnancy.
- Community vector control: Eliminate standing water breeding sites around your home; support community mosquito control programs.
Zika in 2025: Key Questions
Get Outbreak Alerts
regularly updated infectious disease outbreak notifications, delivered free to your inbox.
Zika & Guillain-Barré Syndrome (GBS)
GBS is a rare autoimmune condition where the immune system attacks peripheral nerves, causing ascending paralysis. Zika was the first confirmed viral trigger for GBS at population scale. Epidemiological evidence:
- French Polynesia 2013–2014: GBS incidence increased 20-fold during Zika outbreak
- Brazil 2015–2016: GBS hospitalizations rose sharply in states with active Zika transmission
- Risk: Approximately 1 in 4,000 Zika infections triggers GBS
- Most Zika-associated GBS cases follow the classic ascending weakness pattern; ~5% require mechanical ventilation
- Recovery: 80% of patients recover full function within 6–12 months with appropriate supportive care
Treatment for Zika-GBS follows standard GBS protocols: intravenous immunoglobulin (IVIG) or plasmapheresis, intensive physiotherapy, and respiratory monitoring.
Zika Vaccine Research (2025 Status)
No Zika vaccine has completed Phase 3 trials. The field was deprioritized after 2016 as case counts dropped dramatically, reducing commercial and funding incentives. Current landscape:
- mRNA vaccines (Moderna, NIH): Phase 2 trials paused due to lack of ongoing transmission for efficacy endpoints
- DNA vaccines (Inovio): Phase 2 completed; immunogenic but development stalled
- Subunit/VLP vaccines: Multiple in Phase 1; ZPIV (purified inactivated) showed good immunogenicity
- Live-attenuated: Preclinical stage; promising in NHP models
The WHO maintains Zika on its R&D Blueprint list, and funding can be rapidly mobilized if transmission resurges. The main technical challenge is that vaccine trials need active Zika transmission to test efficacy — a chicken-and-egg problem given the episodic nature of outbreaks.
Current Zika Endemic Zones (2025)
Zika is no longer causing epidemic waves but remains endemic in parts of Africa (where it originated), Southeast Asia, and the Pacific Islands. In the Americas, transmission continues at low levels in tropical regions. Key surveillance concerns:
- Serological surveys suggest widespread prior immunity in Brazilian and Colombian populations, reducing epidemic potential
- Younger birth cohorts (born after 2016) lack immunity and could fuel future outbreaks
- New Aedes albopictus range expansion carries Zika risk to new temperate zones
- WHO surveillance detected Zika in 89 countries as of 2024